INTRODUCTION {#S1}
============

Untreated or poorly treated hypertension is a known predictor of negative coronary artery and cerebrovascular events, and increased morbidity and mortality associated with cardiovascular diseases.[@B1]-[@B3] Hence, adequate control of blood pressure levels to a defined target with appropriate, effective, safe and convenient anti-hypertensive medicines is an important determinant of cardiovascular risk reduction among hypertensive patients.[@B4]-[@B6] Hypertension is an underdiagnosed chronic disease that remains a daunting public health challenge in Nigeria. Notwithstanding a reported prevalence 10% in both urban and rural settings, awareness of blood pressure status remain low, and patients who are lucky to be diagnosed in a formal health care setting often present late and with chronic complications associated with end-organ damage due to malignant hypertension.[@B7],[@B8]

Several studies including one that we conducted and published about ten years ago (June-August 2002) have documented a consistent trend in the prescribing pattern of anti-hypertensive medicines in Nigeria.[@B9] The results often shows thiazide diuretics as the most prescribed anti-hypertensive medicines, followed by short-acting dihydropyridine calcium channel blockers and centrally-acting agent such as methyldopa. Angiotensin converting enzyme inhibitors were often one of the least prescribed anti-hypertensive medicine classes[@B10]-[@B14], while angiotensin receptor blockers were rarely prescribed and used for the management of hypertension in Nigeria at that period. Our previous study of anti-hypertensive medicines utilization pattern about 10 years ago showed that ACEIs and beta blockers were the least frequently prescribed.[@B9] The sparse prescribing of ACEIs was associated with the reported relatively lower reduction of blood pressure by ACEIs in the black population especially as monotherapy.[@B15],[@B16] However, this view was challenged by a number of studies which showed that blood pressure response to ACEIs is probably blind to race but sensitive to patients' factors such as age, body mass index, high entry/baseline blood pressure levels and severe hypertension due to delay in seeking treatment, presence of co-morbidity such as diabetes mellitus and inequity in the access to functional health care.[@B17],[@B18] Furthermore, the appropriate use of the combination of ACEIs with thiazide diuretics in black hypertensive population have been shown to achieve good blood pressure control and improved cardio- and renovascular protection.[@B19],[@B20] Hence, ACEIs appear to provide additional long term benefits beyond adequate control of blood pressures to a defined target. This is important for the black hypertensive patients that are usually at the highest risk of poor prognosis associated with adverse cardiovascular and cerebrovascular events, and higher prevalence of malignant hypertension, chronic kidney disease, left ventricular hypertrophy, congestive heart failure, ischeamic heart disease and myocardial infarction.[@B21],[@B22] Despite the documented evidence of therapeutic benefits associated with the use of ACEIs in black hypertensive patients, studies continue to show that they are one of the least frequently prescribed in Nigeria. The objective of the study was to assess the current utilization of anti-hypertensive medicines with a specific emphasis on identifying possible shift in the frequency of use of ACEIs

METHODS {#S2}
=======

A cross-sectional assessment of the antihypertensive medicines utilization was conducted between 1^st^ June and 31^st^ June 2012 among 300 randomly selected hypertensive patients diagnosed and managed at the Medical Outpatient Clinic of the University College Hospital (UCH), Ibadan. This is a 900-bed premier Teaching Hospital with medical residents located in Ibadan, Southwestern Nigeria. It is affiliated with the University of Ibadan and serves as a major tertiary referral center in Nigeria. UCH has fifty-two service and clinical departments and runs seventy-five consultative outpatient clinics per week in forty-five specialties and sub-specialties. Ibadan, where the study site is located, is one of the largest cities in sub-Saharan Africa and consisted of 11 local government areas. It has an estimated population of

2.5 million consisting of varied backgrounds and ethnicities. Ethical clearance and approval of the study protocols was granted by the Joint University of Ibadan/University College Hospital Research and Ethics Committee. All the patients who presented at the Hypertension unit of the Medical Outpatient Clinics at the study site within the study period were included and constituted the sample frame. The average number of patients seen at the weekly Hypertension clinic was 90. Patient selection was done after clinic appointment cards had been collected and patients were seated in the waiting area. Seventy-five clinic appointment cards were randomly drawn weekly from the collected pool. The case notes of the selected seventy five patients were retrieved for data extraction after physicians' consultation.

Data were extracted from the case notes of the randomly selected 300 patients using pre-tested data collection instruments. The first draft of the instrument was pre-tested with the case notes of ten patients at the study site to assess completeness and relevance of data capture. The final draft of the instrument was modified based on the results of pre-testing, but the data collected during pre-testing was not included in the final result. The data collected from patients' case notes were:

i)Patients' hospital number, Age and Genderii)Systolic and diastolic blood pressure readings at first clinic attendance.iii)Systolic and diastolic blood pressure readings at last clinic attendanceiv)Hypertension diagnosis and co-existing diseases.v)Antihypertensive drugs prescribed with specific focus on ACEIs and ARBs.vi)Documentation of adverse drug reactions associated with ACEIs /ARBs.vii)Baseline and follow-up laboratory monitoring for serum potassium, urea and creatinineviii)Monthly cost of antihypertensive drugs and Monthly cost of ACE inhibitors and ARBs.ix)Potential Drug-drug interactions and contra-indications

The classification of hypertension diagnosis was based on the Seventh report of the Joint National Committee for the prevention, detection, evaluation and treatment of hypertension, and the average systolic / diastolic blood pressure reading recorded at the first clinic attendance were used for the hypertension diagnosis. The documented systolic and diastolic blood pressure levels at the last clinic attendance was adjudge as adequately controlled if they are less than 140/90 mmHg.[@B23] The appropriateness of the antihypertensive drug doses, dosing interval and potentially harmful drug interactions were assessed using the British National Formulary (March, 2010).[@B24] Data analysis was carried out with descriptive and chi-square statistics using Statistical Program for the Social Sciences (SPSS) version 15.0 with p\<0.05 considered significant.

RESULTS {#S3}
=======

The clinico-demographic profile of the random 300 cohort studied is as shown in [Table 1](#T1){ref-type="table"}. The majority (79%) of the cohort were females (237) with mean age of 58.66 (SD=2.81) years (minimum-maximum, 33-97 years). Stage 2 hypertension was the most frequent diagnosis (54.3%) followed by stage 1 hypertension (27.7%) and isolated systolic hypertension (18%). The most frequently diagnosed co-existing diseases were osteoarthritis (38.2%), malaria (22.92%) and diabetes mellitus (20.14%). Overall, blood pressure control was documented as adequate in 33% (96) of cohort.

###### 

Clinic and demographic profile of hypertensive patients.

  -------------------------------------------- -------------------------------------------------- ----- -----------------
  Age (years) (n = 300)                                                                                 

                                               Mean age male                                            66.06 (SD=3.11)

                                               Mean age female                                          58.66 (SD=2.81)

                                                                                                  n     \%

  Gender (n = 300)                             Female                                             237   79

                                               Male                                               63    21

  Hypertension diagnoses                                                                                

                                               Stage 2 hypertension                               163   54.3

                                               Stage 1 hypertension                               83    27.7

                                               Isolated systolic hypertension                     54    18.0

  Co-morbidity (n = 144)                                                                                

                                               Osteoarthritis                                     55    38.2

                                               Malaria                                            33    22.92

                                               Diabetes mellitus                                  29    20.10

                                               Peptic ulcer disease                               9     6.25

                                               Congestive heart failure                           8     5.6

                                               Asthma                                             2     1.39

                                               Psychosis                                          2     1.39

                                               Impaired vision                                    2     1.39

                                               Renal dysfunction                                  1     0.69

                                               Stroke                                             1     0.69

                                               Left ventricular hypertrophy                       1     0.69

                                               Benign prostatic hyperplasia                       1     0.69

  Laboratory Monitoring Tests (n = 300)\                                                                
  (Electrolytes, urea and creatinine levels)                                                            

                                               None                                               189   63

                                               Baseline only                                      104   34.7

                                               Baseline & follow up                               7     2.3

  Cost of anti-hypertensive medicines                                                                   

                                               Mean monthly cost of anti-hypertensive medicines         N 1,784.71

                                               Mean monthly cost of ACE inhibitors                      N 1,114.53
  -------------------------------------------- -------------------------------------------------- ----- -----------------

Calcium channel blockers (36.68%) and Angiotensin converting enzyme inhibitors (ACEIs) (29.93%) were the most frequently prescribed antihypertensive medicine classes. Diuretics, centrally acting agents, and angiotensin II receptor blockers (ARBs) were prescribed in 16.12%, 9.7% and 3.13% of cohort respectively ([Table 2](#T2){ref-type="table"}).

###### 

Pattern of use of antihypertensive and nonantihypertensive drugs.

  ---------------------------------------- -------- -------
  Antihypertensive drugs (n = 608)         number   \%
  Calcium channel blockers (n=223)                  36.68
  Amlodipine                               175      78.5
  Nifedipine                               48       21.5
  ACE Inhibitors (n=182)                            29.93
  Ramipril                                 101      55.5
  Lisinopril                               59       32.4
  Enalapril                                22       12.1
  Thiazide diuretics (n=98)                         16.12
  Amiloride + hydrochlorothiazide          85       86.7
  Hydrochlorothiazide                      13       13.3
  Centrally acting agents (n=59)                    9.7
  Methyldopa                               59       100
  ARB (n=19)                                        3.13
  Losartan                                 18       94.7
  Valsartan                                1        5.3
  Beta blockers (n=15)                              2.47
  Atenolol                                 15       100
  Aldosterone antagonist (n=12)                     1.97
  Spirinolactone                           12       100
  Non-antihypertensive medicines (n=360)            
  Aspirin                                  95       26.39
  Clopidogrel                              73       20.28
  Diclofenac                               37       10.28
  Artemeter + lumefantrine                 33       9.17
  Metformin                                25       6.94
  Glucosamine + chondroitin                14       3.89
  Glimepiride                              14       3.89
  Anxiolytics                              11       3.06
  Calcium lactate                          10       2.78
  Neurobion                                10       2.78
  Meloxicam                                8        2.21
  Mist.Magnesium Trisilicate               6        1.67
  Glibenclamide                            5        1.39
  Orphenadrine                             5        1.39
  Pioglitazone                             4        1.11
  Antipsychotics                           4        1.11
  Omeprazole                               3        0.83
  Digoxin                                  3        0.83
  ---------------------------------------- -------- -------

Amlodipine (78.5%) and ramipril (55.5%) were the most frequently prescribed calcium channel blocker and ACEIs respectively. Amiloride/hydrochlorothiazide combination accounted for 86.73% of prescribed thiazide diuretics, while losartan accounted for 94.74% of the ARBs prescribed. Methyldopa, atenolol and spironolactone were the only centrally acting agent, beta blocker and aldosterone antagonist prescribed in their respective classes ([Table 2](#T2){ref-type="table"}). Aspirin (25.2%), clopidogrel (12.5%) and Non-steroidal Anti-inflammatory Drugs (NSAIDs) were the most frequently non-anti-hypertensive medicines ([Table 2](#T2){ref-type="table"}). All patients made out of pocket payments for their medicines. The mean monthly cost of antihypertensive medicines was NGN1,784.71 ((USD11.09), while the mean monthly cost of ACEIs and ARBs were NGN1,114.5 (USD6.92) and NGN1,376.47 (USD8.55) respectively. The antihypertensive and non-antihypertensive medicines' doses and dosing interval, as documented, were adequate and no contraindication was identified among the cohort studied.

Adverse drug reactions (ADRs) due to ACE1s were documented in 1.5% (3) of cohort with dry cough being the only ADR documented. There was no documentation of ADR for ARBs. Overall, laboratory monitoring of serum potassium, urea and creatinine was conducted in 37% (111) of cohorts. Of these (111), 93.7% (104) had baseline testing of these parameters, while only 6.3% (7) had both baseline and one follow-up testing conducted. Potentially harmful drug-drug interactions were identified in 25% (75) of cohorts. The most frequent potentially-harmful interactions were ACEIs + NSAIDs (53.3%), ACEIs + amiloride / hydrochlorothiazide (22.6%), ACEIs + spironolactone (9.3%), ARBs + amiloride/hydrochlorothiazide (5.3%) and ARBs + spironolactone (5.3%) ([Table 2](#T2){ref-type="table"}).

DISCUSSION {#S4}
==========

The findings of our present study suggest a significant shift in anti-hypertensive prescribing pattern with a considerable increase in the frequency of use of ACEIs and long acting dihyropyridine CCBs. On the other hand we observed a significant downward spiral in the frequency of use of thiazide diuretics (39.4%)[@B9] (ten year ago) to 16.12%. These findings stand in sharp contrast to the anti-hypertensive medicine utilization pattern that we reported from the same study site about 10 years ago.[@B9] The ACEIs were one of the least frequently prescribed accounting for only 8.6% of prescribed anti-hypertensive medicines 10 years ago[@B9]; while the present study showed that the frequency of use has significantly risen to 29.9% (p\<0.0001). This is an important prescribing shift that is likely to contribute to reducing the negative cardiovascular events associated with malignant hypertension, and long term survival among hypertensive patients in Nigeria. The paradigm shift towards increased prescribing of ACEIs probably suggest that clinicians are more cognizant of the long term cardio- and renovascular benefits inherent in using ACEIs especially in a high cardiovascular risk group such as black hypertensive. However, we believe this is not readily clear and will require further studies to identify the factors underlining the significant increase in the prescribing of ACEIs. In addition, the use of thiazide diuretics as first line anti-hypertensive agents among Nigerians with documented high co-morbidities such as diabetes appeared inappropriate ab initio. This is because the landmark Anti-hypertensive and Lipid Lowering Treatment to prevent Heart Attack Trial (ALLHAT) upon which the recommendation to use to thiazides as first line agent is premised reported an increased incidence of hypokalemia, hyperglycemia and new-onset diabetes mellitus with thiazides relative to other anti-hypertensive agents such as ACEIs, ARBs and CCBs.[@B25] Furthermore, other studies have also reported that the incidence of new-onset diabetes mellitus is highest with thiazides and lowest with ACEIs, ARBs.[@B26]-[@B29] Besides, the increased incidence of thiazide-associated hypokalemia is a known contributor to insulin resistance and poor glucose utilization by target tissues.[@B30],[@B31] The long term macro-and microvascular complications associated with this biochemical derangement though well documented are open to confounding by the duration of follow-up and thus may not be readily apparent. Therefore, the shift in anti-hypertensive medicine prescribing pattern is a significant break from the past and it appeared to be based on evidence of obtainable short and long term therapeutic benefits.

The significant prescribing shift from the short acting dihydropyridine CCBs \[Nifedipine: 88.2% (past) versus 21.5% (current)\] reported 10 years ago[@B9] to a long acting CCBs \[amlodipine: 11.8% (past) versus 78.5%% (current)\] (p\<0.0001) also suggest physicians' greater awareness of the importance of using medications with less frequent dosing regimen to improve medication adherence, smoother and better blood pressure control. This is more likely to contribute to the achievement of optimal therapeutic outcomes among patients with hypertension.[@B32]

The decline in the frequency of use of methyldopa between 10 years ago (23.3%)[@B9] and now (9.7%) is also significant (p\<0.0001). Indeed, the current low frequency of methyldopa's use is consistent with its widely reported low or non-usage due to poor safety profile in other countries.[@B23] The widespread availability and cheap acquisition cost of methyldopa, and probably prescribing dogma passed from generations of prescribers upon which the past considerable use of methyldopa was premised appeared to have waned ten years down the line. In addition, the increasing widespread availability of affordable generic version of antihypertensive medicine options with relatively better safety profiles appeared to contribute to the considerable decline in the use of methyldopa. Furthermore, the consideration of the negative impact of low patient adherence associated with medicines with poor ADRs profile such as methyldopa on cardiovascular outcomes in a high risk group such as Nigerian hypertensives may also be contributory.

The lack of an effective ADR monitoring, prevention, detection and documentation system which we reported ten years ago continue to be a sad phenomenon of health care delivery in Nigeria. It is thus unsurprising that ADRs associated with ACEIs and ARBs were documented in only 1.5% of cohorts. This observation is not indicative of low frequency of ADRs but suggest lack of a functional ADRs detection and documentation system. Our position is further supported by the results of the baseline and follow-up laboratory monitoring which showed that majority of patients prescribed ACEIs and ARBs were not adequately monitored with relevant laboratory parameters such serum potassium, urea and creatinine. Yet potentially harmful drug-drug interactions the impact of which could have been easily tracked with relevant laboratory parameters were identified in a majority (75%) of patients. The co-prescribing of NSAIDs and ACEIs in about half of the cohorts without close monitoring required to exclude any potential harms to patients appeared inappropriate and is potentially life-threatening.[@B33],[@B34] The reduced anti-hypertensive efficacy of medicine classes such as ACEIs and thiazide diuretics when co-prescribed on a chronic basis with NSAIDs is well documented.[@B35],[@B36] However, the depth of the contribution of this drug-drug interactions to the observed low level of blood pressure control among the cohorts studied is not readily clear. In addition, the continuing high frequency of co-prescribing of ACEIs and potassium-sparing diuretics such as amiloride + hydrochlorothiazide or aldosterone antagonist such as spironolactone may expose patients to negative cardiovascular events associated with hyperkalemia, especially with the observed poor baseline and follow-up monitoring of serum potassium and creatinine levels.

The result of this study is limited by the fact that patients were sampled at the major tertiary hospital (UCH) in Nigeria. However, the choice of UCH was because it is the premier teaching/tertiary hospital, and a major referral center for other health care centers in Nigeria. Furthermore, it is a major site for undergraduate and post-graduate residency training of physicians. Therefore, the tutelage and practices at UCH as a determinant of clinical practices and prescribing habits of physicians in other parts, or settings, in Nigeria was strongly considered. In addition, the lack of an integrated functional monitoring and documentation system to track patients' progress and long term outcomes of medication use in chronic medical conditions such as hypertension made such long term assessment almost impossible. Furthermore, patient selection appeared skewed towards the female gender. However, the mid-year random sampling strategy, a valid procedure commonly used in epidemiological study, may mitigate probable selection bias. In addition, the observed distribution pattern may also suggests that female hypertensive patients are probably more adherent with clinic attendance or perhaps seeking medical help for the management of hypertension at the study site in relatively greater proportion. This is a probable focus for future research.

CONCLUSIONS {#S5}
===========

Physicians' prescribing of anti-hypertensive medicines in Nigeria appeared to have significantly shift towards increased use of ACEIs and long acting dihydropyridine CCBs, and decline in the use of thiazide diuretics and methyldopa. However, baseline and follow-up monitoring of relevant laboratory parameters to preclude potentially-harmful adverse events and effective detection and documentation of ADRs remain inadequate.
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